RESUMO
Women with severe liver disease often have amenorrhea that resolves as liver disease abates. We describe three patients with mild to moderate chronic liver disease and amenorrhea. In each case amenorrhea resolved when spironolactone therapy was discontinued. We suggest that spironolactone, an androgen inhibitor, may also cause reversible amenorrhea.
Assuntos
Amenorreia/induzido quimicamente , Amenorreia/etiologia , Hepatopatias/complicações , Hepatopatias/tratamento farmacológico , Espironolactona/efeitos adversos , Adolescente , Adulto , Colestase/complicações , Doença Crônica , Feminino , Humanos , Hipertensão Portal/complicações , Hipogonadismo/complicações , Cirrose Hepática/complicações , Linfedema/complicações , Espironolactona/uso terapêutico , SíndromeRESUMO
Growth, neurologic, and ophthalmologic assessments were done in 21 low-birth-weight infants given caffeine for neonatal apnea and in 21 matched control infants. Caffeine significantly decreased the need for and the duration of mechanical ventilation. No difference in growth and development was noted between the control and caffeine-treated infants. A high incidence of cicatricial retrolental fibroplasia was observed in both control (10/21) and caffeine-treated infants (7/18).
Assuntos
Apneia/tratamento farmacológico , Cafeína/uso terapêutico , Desenvolvimento Infantil/efeitos dos fármacos , Doenças do Prematuro/tratamento farmacológico , Apneia/complicações , Cafeína/efeitos adversos , Feminino , Seguimentos , Humanos , Recém-Nascido de Baixo Peso , Recém-Nascido , Ventilação com Pressão Positiva Intermitente/efeitos adversos , Masculino , Doenças do Sistema Nervoso/complicações , Retinopatia da Prematuridade/etiologiaRESUMO
Weekly increments of length, weight, head circumference, and skinfold thickness in response to a series of dietary changes were measured in 108 healthy infants who weighed less than 1.3 kg at birth. The serial manipulations included prevention of late metabolic acidosis, increased caloric intake, and calcium, sodium, and phosphorus supplementation. The study comprised four phases; the infants were divided into ten groups according to dietary regimen. AGA and SGA infants were studied separately. Growth in length was primarily influenced by a change to a formula providing a higher caloric intake and a 60:40 whey protein/casein ratio. Correction of late metabolic acidosis, sodium, and phosphorus supplementation had minor additive effects on growth in length. Increased caloric intake also influenced growth of head circumference, but only in AGA infants. Only the sodium intake was shown to influence body weight increments significantly with the range of caloric intake used in the study (132 to 160 calories/kg/day).